TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Males and females~* Steroid-dependent or multirelapsing NS (defined on the basis of the occurrence of more than 2 relapses in the previous year in spite of steroid and/or other immunosuppressive therapy). Only patients reported to invariably relapse upon treatment tapering or withdrawal who are on stable (from at least 1 month) complete (\<0.3 g/24h for adults or \<4 mg/h/m2 for children) or partial (\<3.5 g/24h for adults or \<40 mg/h/m2 for children) remission of the NS will be included;~* Histological diagnosis of MCD or FSGS or mesangial proliferative GN;~* Written informed consent (or consent from parents or tutors for underage patients).~Exclusion criteria:~* Advanced renal failure (creatinine clearance less than 20 ml/min/1.73m2);~* Evidence of B or C virus infection;~* Refractory or persistent NS;~* Genetic mutations associated with intrinsic abnormalities of the glomerular barrier that would hardly be affected by rituximab treatment;~* Pregnancy or lactating;~* Women of childbearing potential without following a scientifically accepted form of contraception;~* Legal incapacity;~* Evidence of an uncooperative attitude;~* Previous diagnosis of: intellectual disability/mental retardation, dementia, schizophrenia.~* Any evidence that patient will not be able to complete the trial follow-up.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Rituximab (375 mg/m2).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Involving Nursing Home Residents and Their Families in Acute Care Transfer Decisions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult nursing home resident and/or family member or identified significant other of a nursing home resident. Cognitively unimpaired individuals. Long or short term residents of nursing home or rehabilitation center.~Exclusion Criteria:~* Dementia as indicated by score on Mini-Cog. Inability to respond to questions due to physical disability or illness.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decision aid (Type: EXPERIMENTAL): Provision of Go to the Hospital or Stay Here?
- No decision aid (Type: NO_INTERVENTION): Does not receive the decision aid.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previously untreated patients with MCL aged \> 65 years if they are FIT according to the geriatric CGA assessment.~* age 60-65 years not eligible to high-dose chemotherapy plus transplantation, FIT or UNFIT according to the geriatric CGA assessment.~* ECOG performance status ≤ 2.~* Positivity for cyclin D1 and SOX11 \[the latter being mandatory in cases lacking cyclin D1- or t(11;14)-negative\], CD20 and CD5.~* Adequate renal function (Creatinine clearance \> 40 mL/min), with preserved diuresis.~* Adequate liver function: alanine aminotransferase (ALT)/aspartate aminotransferase (AST) \< 2.5 x upper limit of normal (ULN) value, total bilirubin \< 2 mg/dL, unless directly attributable to the patient's tumor.~* Hepatitis B core antibody (HBcAb) positive/HBsAg negative/HBV-DNA negative patients may be enrolled if correct antiviral prophylaxis is administered at least 2 weeks before initiating protocol treatment.~* Written informed consent.~Exclusion Criteria:~* Human immunodeficiency virus (HIV) positive.~* Previous treatment for lymphoma~* Medical conditions or organ injuries that could interfere with administration of therapy.~* Active bacterial, viral, or fungal infection requiring systemic therapy.~* Seizure disorders requiring anticonvulsant therapy.~* Severe chronic obstructive pulmonary disease with hypoxemia.~* History of severe cardiac disease: New York Heart Association (NYHA) functional class III-IV, myocardial infarction within 6 months, ventricular tachyarrhythmias, dilatative cardiomyopathy, or unstable angina.~* Uncontrolled diabetes mellitus.~* Active secondary malignancy.~* Known hypersensitivity or anaphylactic reactions to murine antibodies and proteins, to Bendamustine or mannitol.~* Major surgery within 4 weeks of study Day 1.~* HBsAg+~* HCVAb+ patients with active viral replication (HCV-RNA+ with AST \> 2 x normal limit)~* Any co-existing medical or psychological condition that would preclude participation in the study or compromise the patient's ability to give informed consent, or that may affect the interpretation of the results, or render the patient at high risk from treatment complications.~* CNS involvement (a diagnostic lumbar puncture will be performed in patients with the blastoid variant of MCL)

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- One arm for all patients. (Type: EXPERIMENTAL): Rituximab, Bendamustine, Cytarabine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tracheal Intubation Coaching in NICUs

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. VL coach: Neonatology attending physician position at each neonatal ICU, or Senior trainees who are anticipated to graduate within next 6 months to become neonatology attending physicians.~2. VL coach receivers: Trainees (medical students, residents, fellows except those graduating within next 6 months) and frontline providers (nurse practitioners, hospitalists, physician assistants, respiratory therapists, others who perform tracheal intubations under attending physicians' supervision)~Exclusion Criteria:~None

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Attendings (Type: ACTIVE_COMPARATOR): Study intervention is a VL coaching training for site neonatology attendings. Each site leader/key educator will be trained remotely by expert co-investigators. Site leaders and key educators will train their attendings. The quality of VL coaching skills will be verified by randomly auditing 20% of attending providers at each site for their skill assessment by remote simulation during the transition/post-intervention phase.
- Trainees (Type: NO_INTERVENTION): Trainees will be coached as usual by attendings during their supervised intubation events

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have T1DM based on the disease diagnostic criteria (World Health Organization \[WHO\] Classification).~* Have duration of T1DM ≥1 year.~* Have HbA1c ≤11 %.~* Have been administered with basal-bolus insulins or pre-mixed insulins for at least 90 days prior to screening.~* Have a body mass index (BMI) ≤35 kilograms per meter squared.~Exclusion Criteria:~* Exposure to an insulin glargine other than Lantus® within previous 30 days.~* Have had more than one episode of severe hypoglycemia within 6 months prior to entry into the study.~* Have had more than one episode of diabetic ketoacidosis or emergency room visits for uncontrolled diabetes leading to hospitalization within 6 months prior to entry into the study.~* Have known hypersensitivity or allergy to any of the study insulins (Lantus® or insulin lispro) or to excipients of the study insulins.~* Are pregnant, intend to become pregnant during the course of the study.~* Women who are breastfeeding.~* Are currently taking traditional medicine (herbal medicine or patent medicine) with known/specified content of anti-hyperglycemic effects within 3 months before screening.~* Have congestive heart failure Class III and IV.~* Have obvious clinical signs or symptoms, or laboratory evidence, of liver disease.~* Have any active cancer.~* Have a history or diagnosis of human immunodeficiency virus (HIV) infection.~* Have presence of clinically significant gastrointestinal disease.~* Have a history of renal transplantation, or are currently receiving renal dialysis.~* Are receiving chronic systemic glucocorticoid therapy at pharmacological doses.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY2963016 + Insulin Lispro (Type: EXPERIMENTAL): Participants received 100 units per milliliter (U/mL) LY2963016 administered subcutaneously (SC) once daily (QD) and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.
- Lantus® + Insulin Lispro (Type: ACTIVE_COMPARATOR): Participants received 100 U/mL Lantus® administered SC QD and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 40 - 65 years~* Diagnosed metabolic syndrome~* Risk of cardiovascular death ≥ 5% (according to SCORE)~* Written informed consent~Exclusion Criteria:~* Women not in menopause or not using efficient contraception~* Known hypersensitivity to study drugs~* History of ischemic heart disease

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Fluvastatin: daily 80 mg, oral
- 2 (Type: EXPERIMENTAL): Valsartan
- 3 (Type: EXPERIMENTAL): Hydrochlorothiazide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Age \>18; Able to give informed consent~2. Chronic kidney disease, and estimated GFR 15 to 60 ml/min using the abbreviated MDRD equation~3. intact PTH (iPTH) \>120 pg/ml at baseline~4. albumin corrected calcium \> 8.5 mg/dL to \< 10.0 mg/dL at baseline~5. Phosphorus \< 4.6 mg/dL at baseline~6. If on a phosphorus binder; no change in dose within the 4 weeks prior to screening~Exclusion Criteria~1. Receiving any active form of vitamin D within 4 weeks prior to screening (calcitriol, doxercalciferol; paricalcitol; alfacalcidol)~2. Receiving \>50,000 IU per month of ergocalciferol or \> 1000 IU of cholecalciferol per day within the previous 30 days.~3. history of primary HPT~4. On prednisone \> 30 days within the previous 6 months~5. receiving bisphosphonates or calcitonin within the previous 12 months~6. Non-elective hospitalization within the previous 30 days.~7. Expected to initiate dialysis or receive a kidney transplant within the next 6 mo.~8. History of renal or other organ transplant~9. History of parathyroidectomy or previous diagnosis of primary hyperparathyroidism~10. Receiving cinacalcet within 4 weeks prior to screening.~11. An active drug/alcohol dependence or abuse history~12. History of non-compliance with visits or medications that preclude study compliance in the opinion of the investigator~13. Pregnant, or able to become pregnant and unwilling to use a birth control method considered reliable by the principal investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paricalcitol (Type: EXPERIMENTAL): titrated to achieve 40-60% PTH suppression
- Calcitriol (Type: ACTIVE_COMPARATOR): titrated to achieve 40-60% PTH suppression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adults undergoing liver and/or kidney transplantation~Exclusion Criteria:~* transplant patients with contraindications to tacrolimus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: ACTIVE_COMPARATOR): Standard of Care Tacrolimus Drug Dosing
- Phenotypic Precision Medicine (PPM) (Type: EXPERIMENTAL): PPM-based Computation Assisted Drug Dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Male and female patients with a diagnosis of type 2 diabetes mellitus and previously treated with metformin alone, or with metformin and not more than one other oral antidiabetic drug~2. Diagnosis of type 2 diabetes prior to informed consent~3. Glycosylated haemoglobin A1 (HbA1c)at screening:~   For patients undergoing wash out of previous medication: HbA1c 6.5 - 9.0% For patients not undergoing wash-out of previous medication: HbA1c 7.0 - 10.0%~4. Glycosylated haemoglobin A1 (HbA1c) 7.0 - 10.0% at the beginning of Placebo Run-in~5. Age 18 -80 years~6. BMI (Body Mass Index) less than 40 kg/m2~7. Signed and dated written informed consent by date of Visit 1a in accordance with GCP and local legislation~Exclusion criteria:~1. Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months prior to informed consent~2. Impaired hepatic function~3. Known hypersensitivity or allergy to the investigational product or its excipients or metformin or placebo~4. Treatment with rosiglitazone or pioglitazone within 3 months prior to informed consent~5. Treatment with an injectable GLP-1 analogue (e.g. exenatide) within 3 months prior to informed consent~6. Treatment with insulin within 3 months prior to informed consent~7. Treatment with anti-obesity drugs (e.g. sibutramine, orlistat, rimonabant) within 3 months prior to informed consent~8. Alcohol abuse within the 3 months prior to informed consent that would interfere with trial participation or drug abuse~9. Participation in another trial with an investigational drug within 2 months prior to informed consent~10. Pre-menopausal women who:~    * are nursing or pregnant,~   * or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial.~11. Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent.~12. Renal failure or renal impairment~13. Unstable or acute congestive heart failure~14. Acute or chronic metabolic acidosis (present in patient history)~15. Hereditary galactose intolerance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Linagliptin (Type: EXPERIMENTAL): Patients receive linagliptin 5 mg tablets once daily
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive placebo tablets matching linagliptin 5 mg tablets once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a clinical diagnosis of atopic dermatitis (also known as atopic eczema) for at least 6 months prior to Day 1 that has been clinically stable for at least 1 month prior to Day 1 and is confirmed to be atopic dermatitis according to the criteria of Hanifin and Rajka.~* Have a PGA score of 2 (mild) or 3 (moderate) at Day 1.~* Have atopic dermatitis on the head (including face, but excluding hair bearing scalp), neck, trunk (excluding groin and genitals), or limbs including palms and soles covering at least 2% of total body surface area (BSA) and up to and including 20% of total BSA at Day 1. At least 2% of the total BSA will need to be on the head (including face, but excluding hair bearing scalp), neck, trunk (excluding groin and genitals), or limbs (excluding palms and soles).~Exclusion Criteria:~* Evidence of certain skin conditions/infections at baseline~* Currently have atopic dermatitis on groin, genitals, palm or soles~* Have certain laboratory abnormalities at baseline~* Females who are pregnant, breastfeeding, or are of childbearing potential not using highly effective contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Treatment group A (Type: EXPERIMENTAL): None
- Treatment B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Investigating Ways to Make Local Anaesthetic Hand Surgery Less Painful - Reducing Tourniquet Associated Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy~* More than 18 years of age~Exclusion Criteria:~* Diabetes~* Vascular disease~* Previous operations to arms~* Raynaud's disease~* Analgesia taken in last 24 hours~* Chronic pain~* Hypertension~* Allergy to any substance used in the study~* Unable to give valid consent to participate~* Obesity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Oxygen (Type: ACTIVE_COMPARATOR): Volunteer receives oxygen at a rate of 10litres/minute by mask
- Air (Type: PLACEBO_COMPARATOR): Volunteer receives normal air at a rate of 10litres/minute by mask

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Wilson's disease(adult, infant, pregnant woman)~Exclusion Criteria:~* Acute hepatitis~* Malignant tumor

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NPC-02 (Type: EXPERIMENTAL): zinc acetate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of either NSCLC, SCLC, or mesothelioma, not being treated with curative intent~* Self-reported shortness of breath (a score of 2 or greater on the Modified Medical Research Council Dyspnea Scale)~* Eastern Cooperative Oncology Group (ECOG) Performance Status from 0 (asymptomatic) to 2 (symptomatic and in bed \<50% of day)~* The ability to read and respond to questions English~* Primary cancer care at the Massachusetts General Hospital (MGH) Cancer Center or Dana-Farber Cancer Institute (DFCI)~* Age \>18 years~Exclusion Criteria:~* Cognitive or psychiatric conditions prohibiting study consent or participation.~* A treating clinician who reports that the patient is inappropriate for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: ACTIVE_COMPARATOR): Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians.
- Dyspnea Intervention (Type: EXPERIMENTAL): Dyspnea intervention will be administered over two sessions~Patients will receive:~* Psychoeducation~* Relaxation training for reducing physiological stress~* Behavioral techniques for managing acute breathlessness

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete